Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade

被引：0
|
作者：
Daisuke Obinata
Sho Hashimoto
Hideaki Uchida
Ken Nakahara
Tsuyoshi Yoshizawa
Junichi Mochida
Kenya Yamaguchi
Satoru Takahashi
机构：
[1] Nihon University School of Medicine,Department of Urology
来源：
BMC Urology | / 23卷
关键词：
CRPC; Anti-androgens; Prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876
  • [32] Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
    Stein, Mark N.
    Patel, Neal
    Bershadskiy, Alexander
    Sokoloff, Alisa
    Singer, Eric A.
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 387 - 400
  • [33] Combined androgen blockade for the treatment of metastatic cancer of the prostate
    Schellhammer, PF
    UROLOGY, 1996, 47 (05) : 622 - 628
  • [34] Efficacy of androgen receptor blockade in castration-resistant prostate cancer not dependent on age
    Kuznar, Wayne
    FORMULARY, 2013, 48 (05) : 179 - 179
  • [35] Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel
    Bilgetekin, Irem
    Basal, Fatma Bugdayci
    Cinkir, Havva Yesil
    Esin, Ece
    Oksuzoglu, Berna
    Demirci, Umut
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (08): : 815 - 821
  • [36] Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study
    Sugimoto, Mikio
    Kato, Takuma
    Tohi, Yoichiro
    Shimizu, Yosuke
    Matsumoto, Ryuji
    Inoue, Takahiro
    Takezawa, Yutaka
    Masui, Kimihiko
    Sasaki, Hiroshi
    Hirama, Hiromi
    Saito, Shiro
    Egawa, Shin
    Kamoto, Toshiyuki
    Teramukai, Satoshi
    Kojima, Shinsuke
    Kikuchi, Takashi
    Kakehi, Yoshiyuki
    BMC UROLOGY, 2022, 22 (01)
  • [37] Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
    Mikio Sugimoto
    Takuma Kato
    Yoichiro Tohi
    Yosuke Shimizu
    Ryuji Matsumoto
    Takahiro Inoue
    Yutaka Takezawa
    Kimihiko Masui
    Hiroshi Sasaki
    Hiromi Hirama
    Shiro Saito
    Shin Egawa
    Toshiyuki Kamoto
    Satoshi Teramukai
    Shinsuke Kojima
    Takashi Kikuchi
    Yoshiyuki Kakehi
    BMC Urology, 22
  • [38] Androgen biosynthesis in castration-resistant prostate cancer
    Penning, Trevor M.
    ENDOCRINE-RELATED CANCER, 2014, 21 (04) : T67 - T78
  • [39] Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
    Cora N Sternberg
    Edwina S Baskin-Bey
    Mark Watson
    Andrew Worsfold
    Alex Rider
    Bertrand Tombal
    BMC Urology, 13
  • [40] Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
    Sternberg, Cora N.
    Baskin-Bey, Edwina S.
    Watson, Mark
    Worsfold, Andrew
    Rider, Alex
    Tombal, Bertrand
    BMC UROLOGY, 2013, 13
12345